Systemic Adverse Events after Intravitreal Bevacizumab versus Ranibizumab for Age-Related Macular Degeneration: A Meta-Analysis

Open Access

Peer-reviewed

Research Article

Wei Wang,

Affiliation Zhongshan Ophthalmic Center, State Key Laboratory of Ophthalmology, Sun Yat-Sen University, Guangzhou, People's Republic of China
⨯
Xiulan Zhang

* E-mail: zhangxl2@mail.sysu.edu.cn

Affiliation Zhongshan Ophthalmic Center, State Key Laboratory of Ophthalmology, Sun Yat-Sen University, Guangzhou, People's Republic of China
⨯

Reader Comments (0)

Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.
Macular degeneration
Is the Subject Area "Macular degeneration" applicable to this article?

Thanks for your feedback.
Metaanalysis
Is the Subject Area "Metaanalysis" applicable to this article?

Thanks for your feedback.
Randomized controlled trials
Is the Subject Area "Randomized controlled trials" applicable to this article?

Thanks for your feedback.
Cancer risk factors
Is the Subject Area "Cancer risk factors" applicable to this article?

Thanks for your feedback.
Myocardial infarction
Is the Subject Area "Myocardial infarction" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Medical risk factors
Is the Subject Area "Medical risk factors" applicable to this article?

Thanks for your feedback.